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Abstract 14 
Even in asymptomatic cases of Chlamydia trachomatis infection, the aim of the antibiotic 15 
strategy is eradication of the pathogen so as to avoid the severe late sequelae, such as pelvic 16 
inflammatory disease, ectopic pregnancy, and tubal infertility. Although first-line 17 
antimicrobial agents have been demonstrated to be predominantly successful in the treatment 18 
of C. trachomatis infection, treatment failures have been observed in some cases. Rich source 19 
of antimicrobial peptides was recently discovered in Medicago species, which act in plants as 20 
differentiation factors of the endosymbiotic bacterium partner. Several of these symbiotic 21 
plant peptides have proved to be potent killers of various bacteria in vitro. We show here that 22 
7 of 11 peptides tested exhibited antimicrobial activity against C. trachomatis D, and that the 23 
killing activity of these peptides is most likely due to their interaction with specific bacterial 24 
targets.   25 
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Introduction 29 
 30 
Chlamydia trachomatis is a Gram-negative, obligate intracellular bacterium with a 31 
characteristic biphasic life cycle, forming metabolically inactive infectious forms (elementary 32 
bodies [EBs]) and metabolically active, non-infectious forms (reticulate bodies [RBs]). 33 
Serovars D to K cause urogenital infections that are often asymptomatic, but which can lead 34 
to severe complicated diseases [1]. 35 
 C. trachomatis is of great public health significance because of the impacts of the untreated 36 
diseases on human reproduction. Cervicitis and urethritis commonly occur in women and 37 
about 40% of the untreated cases progress to pelvic inflammatory disease (PID).  Infertility 38 
results in 20% of the PID cases, while 18% of the women with this disease experience chronic 39 
pelvic pain, and 9% may suffer an ectopic pregnancy [2].  40 
At the individual level, C. trachomatis infection can generally be treated effectively with 41 
antibiotics, though antibiotic resistance appears to be increasing [2]. At the population level, 42 
public health control of the infection is rather problematic. With regard to the severe potential 43 
consequences of urogenital C. trachomatis infection in women, many countries offer 44 
screening. Vaccination, which is currently unavailable, would be the best way to reduce the 45 
prevalence of C. trachomatis infections, as it would be much cheaper and would have a 46 
greater impact on controlling C. trachomatis infections worldwide [3]. The development of 47 
new antimicrobial agents is required to overcome this problem.  48 
Antimicrobial peptides (AMPs), natural antibiotics produced by nearly all organisms, from 49 
bacteria to plants and animals, are crucial effectors of innate immune systems, with different 50 
spectra of antimicrobial activity and with the ability to perform rapid killing. To date, more 51 
than 800 AMPs have been discovered in various organisms, including 270 from plants. It has 52 
become clear in recent years that these peptides are able not only to kill a variety of 53 
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pathogens, but also to modulate immune responses in mammals. However, their modes of 54 
action are poorly understood. In some species these peptides serve as the primary 55 
antimicrobial defense mechanism, whereas in others they serve as an adjunct to existing 56 
innate and adaptive immune systems [4]. Cationic AMPs interact with negatively charged 57 
microbial membranes and permeabilize the membrane phospholipid bilayer, resulting in lysis 58 
and the death of microbes [5, 6]. In view of their rapid and broad-spectrum antimicrobial 59 
properties, interest has emerged in AMPs as potential antibiotic pharmaceuticals with which 60 
to combat infections and microbial drug resistance [7, 8]. 61 
Most plant AMPs are cysteine cluster proteins. This group includes major plant immunity 62 
effectors such as defensins, and also symbiotic peptides, including the nodule-specific 63 
cysteine rich (NCR) peptides, which are produced in Medicago -Sinorhizobium meliloti 64 
symbiosis and provoke irreversible differentiation of the endosymbiont. The NCR family is 65 
composed of about 500 divergent peptides in Medicago truncatula [9, 10, 11]. Some cationic 66 
NCRs have been shown to possess genuine antimicrobial activities in vitro, killing various 67 
Gram-negative and Gram-positive bacteria highly efficiently [12]. 68 
In the present study, 7 of the 11 NCR peptides examined displayed dose- and time-dependent 69 
anti-chlamydial activity in vitro. NCR247 was also demonstrated to bind to the 60-kDa 70 
putative GroEL protein of C. trachomatis D.   71 
 72 
Materials and Methods 73 
Inoculum preparation 74 
C. trachomatis D (ATCC) was propagated on HeLa cells as described earlier [13]. The 75 
partially purified and concentrated EBs were aliquoted and stored at -80 °C until use. A mock 76 
preparation was prepared from an uninfected HeLa cell monolayer processed in the same way 77 
as the infected cells. The titer of the infectious EBs was determined by indirect 78 
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immunofluorescence assay. Serial dilutions of the EB preparation were inoculated onto tissue 79 
culture monolayers and, after a 48-h culture, cells were fixed with acetone and stained with 80 
murine monoclonal anti-Chlamydia LPS antibody (AbD Serotec, Oxford, UK) and FITC-81 
labeled secondary anti-mouse IgG (Sigma, St. Louis, MO, USA). The number of inclusions 82 
was counted under a UV microscope, and the titer was expressed in inclusion forming 83 
units/ml (IFU/ml).  84 
 85 
Measurement of in vitro antibacterial activity of NCR peptides 86 
First, the toxicity of the NCR peptides was tested on non-infected HeLa cells in the highest 87 
concentration (10 g/ml) used during our experiments. The toxic peptides were excluded 88 
from the further experiments.  89 
EBs of C. trachomatis D (4 × 104 IFU/ml) were incubated with chemically synthesized 90 
mature NCR030 (AFLPTSRNCITNKDCRQVRNYIARCRKGQCLQSPVR pI=10,37); 91 
NCR044 (AFIQLSKPCISDKECSIVKNYRARCRKGYCVRRRIR pI=10,32); NCR055 92 
(VNDCIRIHCKDDFDCIENRLQVGCRLQREKPRCVNLVCRCLRR pI=9,21); NCR095 93 
(ELVCDTDDDCLKFFPDNPYPMECINSICLSLTD pI=3,62); NCR137 94 
(MTLRPCLTDKDCPRMPPHNIKCRKGHCVPIGKPFK pI=9,7); NCR168 95 
(YPFQECKVDADCPTVCTLPGCPDICSFPDVPTCIDNNCFCT pI=3,61); NCR169 96 
(EDIGHIKYCGIVDDCYKSKKPLFKIWKCVENVCVLWYK pI=8,45); NCR183 97 
(ITISNSSFGRIVYWNCKTDKDCKQHRGFNFRCRSGNCIPIRR pI=10,1); NCR192 98 
(MKNGCKHTGHCPRKMCGAKTTKCRNNKCQCVQL pI=9,54); NCR247 99 
(RNGCIVDPRCPYQQCRRPLYCRRR pI=10,15); or NCR280 100 
(MRVLCGRDGRCPKFMCRTFL pI=9,8) (Proteogenix Oberhausbergen, France) at various 101 
concentrations (10, 5, 2.5, or 1.25 μg/ml) in sucrose-phosphate-glutamic acid buffer (SPG) for 102 
2 h at 37 °C. As control, C. trachomatis D was incubated in buffer alone. The time courses of 103 
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the anti-chlamydial effects of the NCR peptides were tested after incubation periods of 15, 30, 104 
60 and 120 min. To quantify the anti-chlamydial effects of the NCR peptides, HeLa cells were 105 
seeded in 24-well tissue culture plates with 13-mm cover glasses. After 24 h, the confluent 106 
cells were infected with NCR-treated C. trachomatis D or the control. After 48 h, the cells 107 
were fixed with acetone at −20 °C for 10 min. Fixed cells on cover glasses were stained by 108 
the indirect immunofluorescence method described in “Inoculum preparation” section. The 109 
number of recoverable inclusions was counted under a UV microscope, and the titre was 110 
expressed in IFU/ml.  111 
 112 
Far-Western blot assay for identification of NCR-binding Chlamydia proteins 113 
Concentrated C. trachomatis (2 × 105 IFU) (prepared as described earlier) and a mock 114 
preparation were heated at 95 °C for 5 min in sample buffer, and polyacrylamide gel 115 
electrophoresis (PAGE) was performed. The proteins were separated on 10% sodium dodecyl 116 
sulfate (SDS) polyacrylamide gel in duplicate, and half of the gel carrying the separated 117 
proteins of the C. trachomatis or the mock samples was blotted onto a polyvinylidene 118 
difluoride membrane (SERVA, Heidelberg, Germany). The membrane was blocked overnight 119 
at 4 °C with 5% skimmed milk and 0.05% Tween 20 containing PBS. The membrane was 120 
probed for 4 h with a buffer [1% bovine serum albumin in PBS with 0.05% Tween 20 121 
(PBST)] containing 10 μg/ml NCR247. After washing 3 times with PBST, the filter was 122 
incubated with anti-NCR247 rabbit IgG for 4 h and further incubated after washing 3 times 123 
with HRP-conjugated anti-rabbit antibody (Sigma). A control lane with separated C. 124 
trachomatis EBs was also incubated with anti-NCR247 and HRP-conjugated anti-rabbit 125 
antibody without prior treatment with NCR247 peptide. Following 3 further washings, the 126 
colour was developed by using diaminobenzidine tetrahydrochloride (Sigma) with hydrogen 127 
peroxide in 10 mM Tris at pH 7.5. The second half of the gel with the separated proteins of C. 128 
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trachomatis or the mock preparation was stained with PageBlue Protein Staining Solution 129 
(Fermentas). 130 
 131 
Identification of proteins by mass spectrometry 132 
The gel slices containing the polypeptides of the concentrated C. trachomatis EBs 133 
corresponding to proteins exhibiting NCR247 positivity in the blotting assay were cut out 134 
from the gel and analyzed by mass spectrometry. Briefly, protein bands were diced and 135 
washed with 25 mM NH4HCO3 in 50% (v/v) acetonitrile/water. Disulphide bridges were 136 
reduced with dithiothreitol (DTT), and free sulphydryls were alkylated with iodoacetamide. 137 
Proteins were digested with modified porcine trypsin (Promega Madison, WI, USA) for 4 h at 138 
37 °C. Samples were analysed on liquid chromatography-tandem mass spectrometry (LC-139 
MSMS) instruments. LC-MSMS raw data were converted into a Mascot generic file with 140 
Mascot Distiller software (v2.1.1.0). The resulting peak lists were searched by using the 141 
Mascot Daemon software (v2.2.2) against the NCBI non-redundant database without species 142 
restriction (NCBInr 20080718, 6833826 sequences). Monoisotopic masses with a peptide 143 
mass tolerance of ±0.6 Da and a fragment mass tolerance of 1 Da were submitted. 144 
Carbamidomethylation of Cys was set as a fixed modification, and acetylation of protein N-145 
termini, methionine oxidation, and pyroglutamic acid formation from peptide N-terminal Gln 146 
residues were permitted as variable modifications. Acceptance criteria were at least 2 147 
individual peptides with a minimum peptide score of 55 per protein. 148 
 149 
Detection of NCR peptide binding to Chlamydia EBs by FACS 150 
 151 
Chlamydia EBs (1 × 106 IFU) were treated with 1 μg of FITC-labelled NCR247 or FITC-152 
labelled NCR035 peptide containing PBS for 2 h at 37 °C. As controls, untreated Chlamydia 153 
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EBs were used. After 3 times washing with PBS, cells were analyzed with the FACS StarPlus 154 
(Becton Dickinson) device. 155 
  156 
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Results 157 
 158 
Anti-chlamydial effect of plant peptides.  159 
To determine whether they possess anti-chlamydial activity, 11 NCR peptides (NCR030, 160 
NC0R44, NCR055, NCR095, NCR137, NCR168, NCR169, NCR183, NCR192, NCR247 and 161 
NCR280) were co-incubated individually with C. trachomatis EBs at 10 g/ml for 2 h at 37 162 
°C. Counting of the number of viable C. trachomatis inclusions demonstrated that 7 of the 11 163 
peptides (NCR044, NCR055, NCR095, NCR183, NCR192, NCR247 and NCR280) were 164 
effective killers of C. trachomatis in vitro, while NCR030 and NCR168 displayed weaker 165 
activity and NCR137 and NCR169 did not exert an anti-chlamydial effect (Fig. 1A). C. 166 
trachomatis inclusions were then treated for 2 h with concentrations of the peptides ranging 167 
from 1.25 μg/ml to 10 μg/ml (Fig. 1B). NCR044, NCR055 and NCR183 were found to exert 168 
the strongest anti-chlamydial activities by reducing the viability to 95%, 78% and 85%, 169 
respectively, at 1.25 μg/ml, whereas the other peptides revealed no effect at 1.25 μg/ml 170 
concentration. NCR192 and NCR247 had significant anti-chlamydial effects at 2.5 g/ml 171 
concentration. The time course of killing was investigated in the cases of NCR044, NCR055, 172 
NCR183 and NCR247 at 5 μg/ml concentration (Fig. 1C). NCR044 elicited the fastest effect, 173 
achieving an 80% reduction in the number of viable Chlamydia inclusions after a 15-min co-174 
incubation with C. trachomatis EBs. The other three peptides required longer times to attain 175 
the killing effect. Of the tested peptides therefore, NCR044 exhibited the strongest anti-176 
chlamydial activity, acting at the lowest concentration and most rapidly. 177 
 178 
 179 
 180 
 181 
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Identification of the chlamydial ligand responsible for NCR247 binding  182 
Further investigations were carried out with NCR247, which displayed anit-chlamydial 183 
activity in the previous tests.  184 
To identify the chlamydial ligand responsible for NCR peptide binding, concentrated C. 185 
trachomatis EB preparations and mock control preparations were separated by SDS-PAGE. 186 
After blotting, the membranes were probed with synthetic NCR247 peptide and incubated 187 
with anti-NCR247 IgG and then with HRP-labeled anti-rabbit antibody. The control lane with 188 
Chlamydia EBs was stained with anti-NCR247 IgG and HRP-labeled anti-rabbit antibody 189 
without incubation with synthetic NCR247 peptide. The synthetic NCR247 peptide was 190 
bound to a 60-kDa protein band in the Chlamydia lysate (Fig. 2A, lane 4). The synthetic 191 
NCR247 did not react with the mock lysate (lane 2), and the Chlamydia EB lysate did not 192 
react with the HRP-conjugated anti-rabbit antibody (lane 3). The gel slice containing the 193 
corresponding polypeptide of the concentrated C. trachomatis EBs associated with the 194 
synthetic NCR247 peptide was cut out from the gel and analyzed by LC-MSMS. A 60 kDa 195 
putative GroEL protein of Chlamydia was indicated by LC-MSMS and confirmed by post 196 
source decay analysis (Fig. 2B). 197 
 198 
FACS analysis for the detection of NCR247 binding to the whole C. trachomatis EBs 199 
To show that NCR247 is able to bind not only to the degraded Chlamydia particles but to the 200 
native, viable Chlamydia EBs, a FACS analysis was carried out. Fig. 3 reveals that Chlamydia 201 
EBs interacted with FITC-conjugated NCR247 peptide. Untreated or FITC-labeled NCR035 202 
peptide-treated (this peptide showed no anti-chlamydial effect earlier) Chlamydia EBs did not 203 
demonstrate increased fluorescence.   204 
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Discussion 205 
C. trachomatis is the leading cause of sexually transmitted bacterial diseases in both 206 
developed and developing countries, with more than 90 million new cases of genital 207 
infections occurring annually. The development of effective new antimicrobial compounds is 208 
indispensable if the late severe sequelae of the infections, such as ectopic pregnancy and 209 
infertility, are to be avoided [14]. AMPs appear to be potentially promising candidates for this 210 
purpose. Although their antimicrobial activity against bacteria, fungi and protozoa has been 211 
extensively tested [15], their anti-chlamydial action has not yet been tested. In the present 212 
study, therefore, we investigated the in vitro activity of 11 NCR peptides against C. 213 
trachomatis. Seven of these peptides exerted significant anti-chlamydial activity at a 10 g/ml 214 
concentration. A number of synthetic NCR peptides from Medicago truncatula have been 215 
reported to be potent killers of various Gram-negative (Escherichia coli, Salmonella 216 
Typhimurium, Agrobacterium tumefaciens, Pseudomonas aeruginosa and Xanthomonas 217 
campestris) and Gram-positive (Bacillus megaterium, Bacillus cereus, Clavibacter 218 
michiganensis, Staphylococcus aureus and Listeria monocytogenes) bacteria, including 219 
human/animal and plant pathogens [12]. Furthermore, AMPs were effective against 220 
Staphylococcus epidermidis in in vivo mouse model, and they also displayed anti-221 
inflammatory activity [8].  222 
Our LC-MSMS experiment identified the GroEL protein of C. trachomatis as the 223 
chlamydial ligand of the NCR247 peptide. The GroEL protein is one of the few proteins that 224 
have so far been confirmed as relevant in chlamydial pathogenesis; it is also referred to as 225 
heat shock protein 60 (Hsp60) [16]. This protein belongs to group I chaperones produced by 226 
almost all prokaryotic and eukaryotic cells, which assist as intracellular proteins, in the correct 227 
folding of nascent or denatured proteins under both normal and stress conditions [17].  228 
Several reports have indicated that molecular chaperones produced by pathogenic bacteria, 229 
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can function as intracellular, cell surface, or extracellular signals in the course of infection 230 
processes [18]. The immune responses to chlamydial GroEL correlate significantly with 231 
disease sequelae in humans, and 80 to 90% of patients infected with C. trachomatis have 232 
antibodies directed against GroEL [19]. The high degree of antigenicity of GroEL in patients 233 
implies that the protein is easily accessible to the immune system, perhaps because it is 234 
localized on the surface of the chlamydial particles. Early studies on isolated outer membrane 235 
complexes from C. trachomatis and Chlamydophila psittaci EBs had indeed pointed to the 236 
possibility that GroEL might be associated with chlamydial membranes [20]. Taken together, 237 
GroEL is accessible for the binding of the NCR247 peptide. 238 
The present study indicates that certain of the NCR peptides possess substantial in 239 
vitro activity against C. trachomatis D. Studies of chlamydial infection in animal models are 240 
clearly needed to establish whether they have parallel in vivo results and whether these 241 
peptides can be useful lead compounds for the development of anti-chlamydial drugs. 242 
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Figures 315 
 316 
Fig. 1. Concentration and time dependences of the anti-chlamydial effects of NCR peptides. 317 
C. trachomatis at 4x104 IFU/ml was incubated with 10 g/ml of synthetic NCR peptide for 2 318 
h at 37 °C (A). C. trachomatis EBs were incubated with different quantities of synthetic NCR 319 
peptides for 2 h at 37 °C (B) C. trachomatis was co-incubated individually with different 320 
NCR peptides (5 g/ml) for 0, 15, 30, 60 or 120 min (C). The infectivity of the NCR peptide-321 
treated C. trachomatis was determined by inoculating the mixture onto confluent HeLa cells 322 
on cover glasses. After a 24-h incubation, the fixed cells were stained with anti-chlamydia 323 
LPS antibody and the number of inclusions was counted under a UV microscope. All the data 324 
are representative of three separate experiments.  325 
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Fig. 2. Interaction of NCR247 peptide and C. trachomatis EBs. Far-Western blot analysis of 331 
the chlamydial ligands responsible for NCR247 peptide binding. (A) Concentrated C. 332 
trachomatis and mock control preparations were separated by SDS-PAGE. After blotting, the 333 
membrane (lane 2,4) was probed with synthetic NCR247 peptide and incubated with anti-334 
NCR247 IgG and HRP-labelled anti-rabbit antibody. (lane 1- molecular weight marker, lane 2 335 
- mock preparation, lane  4 - Chlamydia EBs lysate). A control lane (lane 3) with separated C. 336 
trachomatis EBs was also incubated with anti-NCR247 and HRP-conjugated anti-rabbit 337 
antibody without prior treatment with the NCR247 peptide. Identification of the C. 338 
trachomatis proteins by LC-MSMS (B). Peptide fragments that match the defined protein 339 
sequences are to be found in the Table.  340 
 341 
 342 
  343 
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Fig. 3. FACS analysis of NCR247 peptide binding to whole C. trachomatis EBs. Untreated 344 
and unstained Chlamydia EBs (A). FITC-labelled NCR247 peptide treated C. trachomatis 345 
EBs (B). Chlamydia EBs treated with FITC-labelled NCR035 peptide (C). 346 
 347 
 348 
 349 
